한글목차

세계의 바이러스 벡터 및 플라스미드 DNA 시장 규모는 2023년 29억 달러에서 예측 기간 동안 19.7%의 CAGR을 기록하며 2028년 말에는 71억 달러 규모로 성장할 것으로 예상됩니다.

바이러스 벡터 기술 시장은 2023년 18억 달러 규모에서 2028년 말에는 45억 달러 규모로 2028년까지 연평균 20.7% 성장할 것으로 예측됩니다. 플라스미드 DNA 기술 시장은 2023년 11억 달러에서 2028년 말까지 17.9%의 CAGR을 기록하며 26억 달러 규모로 성장할 것으로 예상됩니다.

세계의 바이러스 벡터 및 플라스미드 DNA 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별 상세 분석, 임상시험 및 특허 동향, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 주요 요약

• 시장 전망
• 조사 범위
• 시장 요약

제2장 시장 개요

• 바이러스 기술
• 세포 및 유전자 치료

제3장 시장 역학

• 시장 역학
• 성장 촉진요인
• 기회
• 성장 억제요인
• 과제

제4장 신기술과 개발

• 개요
• 바이러스 벡터 생산의 AI
• Doggy Bone DNA
• FRAGment Recycler : 플라스미드 DNA 합성의 신기술
• 특허
• 제조업체별 특허 보유 상황
• 임상시험
• 바이러스 벡터와 플라스미드 DNA 기술의 임상시험

제5장 세계의 바이러스 벡터 및 플라스미드 DNA 기술 시장

• 분류
• 시장 내역 : 제품 유형별
• 시장 내역 : 최종사용자별
• 연구기관
• 제약·바이오의약품 기업
• 시장 내역 : 용도별
• 암
• 유전성 질환
• 감염증
• 심혈관질환
• 기타 질병
• 지역적 내역
• 시장 내역 : 지역별
• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 기타 지역

제6장 경쟁 정보

• 업계 시나리오
• 기업 점유율
• 기업 간의 경쟁 상황
• 경쟁 상황 : 바이러스 벡터
• 경쟁 상황 : 플라스미드 DNA

제7장 바이러스 벡터 및 플라스미드 DNA 기술 시장의 지속가능성 : ESG 관점

• 환경 요인
• 사회 요인
• 거버넌스 요인
• 주요 기업의 ESG 퍼포먼스
• 주요 기업의 ESG 퍼포먼스
• Lonza : ESG 퍼포먼스
• Thermo Fisher Scientific : ESG 퍼포먼스
• 결론

제8장 부록

• 조사 방법
• 두문자어
• 참고문헌
• 기업 개요
• AGILENT TECHNOLOGIES INC.
• BLUEBIRD BIO INC.
• CATALENT INC.
• DANAHER CORP.
• FUJIFILM HOLDINGS CORP.
• GENSCRIPT
• GILEAD SCIENCES INC.
• LONZA
• NOVARTIS AG
• OXFORD BIOMEDICA PLC
• PLASMIDFACTORY GMBH
• REGENXBIO INC.
• THERMO FISHER SCIENTIFIC INC.
• VGXI INC.

영문목차

The global market for viral vector and plasmid DNA technologies is expected to grow from $2.9 billion in 2023 to $7.1 billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.7% from 2023 through 2028.

The global market for viral vector technology is expected to grow from $1.8 billion in 2023 to $4.5 billion by the end of 2028, at a CAGR of 20.7% from 2023 through 2028.

The global market for plasmid DNA technology is expected to grow from $1.1 billion in 2023 to $2.6 billion by the end of 2028, at a CAGR of 17.9% from 2023 through 2028.

Report Scope:

The report provides a comprehensive summary of the viral vector and plasmid DNA technologies market focusing cell and gene therapies, along with detailed competitive landscape and profiles of key market players that include revenue, product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges, and opportunities. This research study discusses historical, current, and potential market size. The report will enable market players and new entrants to make informed decisions about the production and licensing of goods and services. Organizations, distributors, and exporters should find the information about market development and trends useful. The study segments the market on the basis of product type, applications, and end use. Geographical market analysis is provided for all the major segments. The report offers country-level analysis of markets to provide a better understanding of the major segments.

The market is divided into segments and by application/industry as follows:

By product type:

Viral vector.

Plasmid DNA.

By application:

Cancer.

Genetic disorders.

Infectious diseases.

Cardiovascular diseases.

Other diseases.

By end-user:

Research institutes.

Pharmaceutical and biopharmaceutical companies.

Each area is covered in detail, identifying current products in the market in the base year (2022), measuring the current market size and identifying current and potential market drivers, forecasting for 2028, assessing current and potential competitors, and identifying current competitor market shares for 2022.

Report Includes:

• 93 data tables and 47 additional tables
• An overview of the global market for viral vector and plasmid DNA
• Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Evaluation of the current market size and revenue growth prospects for viral vector and plasmid DNA, along with a market share analysis by product type, application and geographic region
• A look at the innovations, technological advances, and product launches from leading companies
• Analysis of the industry's regulatory framework and policies, and its product pipeline
• Discussion of ESG challenges and ESG practices
• Analysis of the key companies' market shares, proprietary technologies, strategic alliances and other market strategies, and patents
• Profiles of the leading players in the industry

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Viral Technology
• Cell and Gene Therapy

Chapter 3 Market Dynamics

• Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges

Chapter 4 Emerging Technologies and Developments

• Overview
• AI in Viral Vector Production
• Doggy Bone DNA
• FRAGment Recycler: A New Technology for Plasmid DNA Synthesis
• Patents
• Patent Holdings by Manufacturer
• Clinical Trials
• Selected Clinical Trials of Viral Vectors and Plasmid DNA Technologies

Chapter 5 Global Market for Viral Vector and Plasmid DNA Technologies

• Segmentation Breakdown
• Market Breakdown by Product Type
• Market Breakdown by End User
• Research Institutes
• Pharmaceutical and Biopharmaceutical Companies
• Market Breakdown by Application
• Cancer
• Genetic Disorders
• Infectious Diseases
• Cardiovascular Diseases
• Other Diseases
• Geographic Breakdown
• Market Breakdown by Region
• North America
• Latin America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 6 Competitive Intelligence

• Industry Scenario
• Company Shares
• Competitive Landscape among Companies
• Competitive Landscape in Viral Vectors
• Competitive Landscape in Plasmid DNA

Chapter 7 Sustainability in the Market for Viral Vector and Plasmid DNA Technologies: An ESG Perspective

• Introduction
• Environmental Factors
• Social Factors
• Governance Factors
• ESG Performance among Major Companies
• ESG Performance of Select Companies
• Lonza: ESG Performance
• Thermo Fisher Scientific: ESG Performance
• Conclusion

Chapter 8 Appendix

• Research Methodology
• Acronyms
• References
• Company Profiles
• AGILENT TECHNOLOGIES INC.
• BLUEBIRD BIO INC.
• CATALENT INC.
• DANAHER CORP.
• FUJIFILM HOLDINGS CORP.
• GENSCRIPT
• GILEAD SCIENCES INC.
• LONZA
• NOVARTIS AG
• OXFORD BIOMEDICA PLC
• PLASMIDFACTORY GMBH
• REGENXBIO INC.
• THERMO FISHER SCIENTIFIC INC.
• VGXI INC.